584 related articles for article (PubMed ID: 23264591)
1. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins.
Schaer DJ; Buehler PW; Alayash AI; Belcher JD; Vercellotti GM
Blood; 2013 Feb; 121(8):1276-84. PubMed ID: 23264591
[TBL] [Abstract][Full Text] [Related]
2. Modular Platform for the Development of Recombinant Hemoglobin Scavenger Biotherapeutics.
Buzzi RM; Owczarek CM; Akeret K; Tester A; Pereira N; Butcher R; Brügger-Verdon V; Hardy MP; Illi M; Wassmer A; Vallelian F; Humar R; Hugelshofer M; Buehler PW; Gentinetta T; Schaer DJ
Mol Pharm; 2021 Aug; 18(8):3158-3170. PubMed ID: 34292741
[TBL] [Abstract][Full Text] [Related]
3. When might transferrin, hemopexin or haptoglobin administration be of benefit following the transfusion of red blood cells?
Buehler PW; Karnaukhova E
Curr Opin Hematol; 2018 Nov; 25(6):452-458. PubMed ID: 30281034
[TBL] [Abstract][Full Text] [Related]
4. Intravenous infusion of haptoglobin for the prevention of adverse clinical outcome in Sickle Cell Disease.
Quimby KR; Hambleton IR; Landis RC
Med Hypotheses; 2015 Oct; 85(4):424-32. PubMed ID: 26141635
[TBL] [Abstract][Full Text] [Related]
5. The Mechanism of Proinflammatory HDL Generation in Sickle Cell Disease Is Linked to Cell-Free Hemoglobin via Haptoglobin.
Ji X; Feng Y; Tian H; Meng W; Wang W; Liu N; Zhang J; Wang L; Wang J; Gao H
PLoS One; 2016; 11(10):e0164264. PubMed ID: 27716784
[TBL] [Abstract][Full Text] [Related]
6. Engineering Therapeutics to Detoxify Hemoglobin, Heme, and Iron.
Pires IS; Berthiaume F; Palmer AF
Annu Rev Biomed Eng; 2023 Jun; 25():1-21. PubMed ID: 37289555
[TBL] [Abstract][Full Text] [Related]
7. Different target specificities of haptoglobin and hemopexin define a sequential protection system against vascular hemoglobin toxicity.
Deuel JW; Vallelian F; Schaer CA; Puglia M; Buehler PW; Schaer DJ
Free Radic Biol Med; 2015 Dec; 89():931-43. PubMed ID: 26475040
[TBL] [Abstract][Full Text] [Related]
8. Haptoglobin Therapeutics and Compartmentalization of Cell-Free Hemoglobin Toxicity.
Buehler PW; Humar R; Schaer DJ
Trends Mol Med; 2020 Jul; 26(7):683-697. PubMed ID: 32589936
[TBL] [Abstract][Full Text] [Related]
9. Hemolysis, free hemoglobin toxicity, and scavenger protein therapeutics.
Vallelian F; Buehler PW; Schaer DJ
Blood; 2022 Oct; 140(17):1837-1844. PubMed ID: 35660854
[TBL] [Abstract][Full Text] [Related]
10. The Role of Circulating Cell-Free Hemoglobin in Sepsis-Associated Acute Kidney Injury.
Kerchberger VE; Ware LB
Semin Nephrol; 2020 Mar; 40(2):148-159. PubMed ID: 32303278
[TBL] [Abstract][Full Text] [Related]
11. New Insights into Hemopexin-Binding to Hemin and Hemoglobin.
Lechuga GC; Napoleão-Pêgo P; Morel CM; Provance DW; De-Simone SG
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409149
[TBL] [Abstract][Full Text] [Related]
12. Haptoglobin Preserves Vascular Nitric Oxide Signaling during Hemolysis.
Schaer CA; Deuel JW; Schildknecht D; Mahmoudi L; Garcia-Rubio I; Owczarek C; Schauer S; Kissner R; Banerjee U; Palmer AF; Spahn DR; Irwin DC; Vallelian F; Buehler PW; Schaer DJ
Am J Respir Crit Care Med; 2016 May; 193(10):1111-22. PubMed ID: 26694989
[TBL] [Abstract][Full Text] [Related]
13. Corynebacterium diphtheriae Iron-Regulated Surface Protein HbpA Is Involved in the Utilization of the Hemoglobin-Haptoglobin Complex as an Iron Source.
Lyman LR; Peng ED; Schmitt MP
J Bacteriol; 2018 Apr; 200(7):. PubMed ID: 29311283
[No Abstract] [Full Text] [Related]
14. Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in guinea pigs by haptoglobin therapy.
Baek JH; D'Agnillo F; Vallelian F; Pereira CP; Williams MC; Jia Y; Schaer DJ; Buehler PW
J Clin Invest; 2012 Apr; 122(4):1444-58. PubMed ID: 22446185
[TBL] [Abstract][Full Text] [Related]
15. The role of RBC destruction in vascular regions with high turbulence on atherosclerosis.
Olgun A; Akman S; Erbil MK
Med Hypotheses; 2004; 63(2):283-4. PubMed ID: 15236792
[TBL] [Abstract][Full Text] [Related]
16. Depletion of haptoglobin and hemopexin promote hemoglobin-mediated lipoprotein oxidation in sickle cell disease.
Yalamanoglu A; Deuel JW; Hunt RC; Baek JH; Hassell K; Redinius K; Irwin DC; Schaer DJ; Buehler PW
Am J Physiol Lung Cell Mol Physiol; 2018 Nov; 315(5):L765-L774. PubMed ID: 30047285
[TBL] [Abstract][Full Text] [Related]
17. Haptoglobin, hemopexin, and related defense pathways-basic science, clinical perspectives, and drug development.
Schaer DJ; Vinchi F; Ingoglia G; Tolosano E; Buehler PW
Front Physiol; 2014; 5():415. PubMed ID: 25389409
[TBL] [Abstract][Full Text] [Related]
18. Assessment of total and unbound cell-free heme in plasma of patients with sickle cell disease.
Vissa M; Larkin SK; Vichinsky EP; Kuypers FA; Soupene E
Exp Biol Med (Maywood); 2023 May; 248(10):897-907. PubMed ID: 36941786
[TBL] [Abstract][Full Text] [Related]
19. Hemopexin increases the neurotoxicity of hemoglobin when haptoglobin is absent.
Chen-Roetling J; Ma SK; Cao Y; Shah A; Regan RF
J Neurochem; 2018 Jun; 145(6):464-473. PubMed ID: 29500821
[TBL] [Abstract][Full Text] [Related]
20. Haptoglobin and hemopexin inhibit vaso-occlusion and inflammation in murine sickle cell disease: Role of heme oxygenase-1 induction.
Belcher JD; Chen C; Nguyen J; Abdulla F; Zhang P; Nguyen H; Nguyen P; Killeen T; Miescher SM; Brinkman N; Nath KA; Steer CJ; Vercellotti GM
PLoS One; 2018; 13(4):e0196455. PubMed ID: 29694434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
